BG Medicine, Inc.
BGMD
Other OTC0.00
USD
- -
- -
ISIN
US08861T2069
CUSIP
08861T206
Return %
Stock
S&P500
1Y
0.00
26.53
3Y
- -
76.60
5Y
-99.87
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Stephen Hall
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 303 Wyman Street Waltham MA United States of America 02451
- IPO Date
- Feb 4, 2011
- Website
- bg-medicine.com
- Similar Companies
- Business
- BG Medicine, Inc. is a commercial-stage diagnostics company specializing in the development and commercialization of cardiovascular diagnostic tests primarily focused on heart failure and related disorders. The company’s core products include the BGM Galectin-3 Test, an in vitro diagnostic assay that measures galectin-3 levels in serum or plasma through enzyme-linked immunosorbent assay (ELISA) on a microtiter plate platform, and the CardioSCORE Test, a multi-analyte biomarker-based blood test for assessing near-term risk of atherothrombotic cardiovascular events such as heart attack and ischemic stroke. BG Medicine licenses development and commercialization rights for automated versions of its galectin-3 test to major partners including Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. The company collaborates with Abbott Laboratories to develop and commercialize galectin-3 assay kits and related reagents for clinical use. BG Medicine operates primarily in the United States and targets healthcare providers and clinical laboratories in the cardiovascular diagnostics market. Founded in 2000 and headquartered in Waltham, Massachusetts, BG Medicine transitioned from its former name Beyond Genomics, Inc. in October 2004 to reflect its focus on biomarker-driven diagnostics. Recently, the company has experienced notable operational activity including board changes and a strategic withdrawal of its 510(k) premarket notification for a proposed additional indication for its BGM Galectin-3 Test. These adjustments indicate a recalibration of regulatory and commercial strategies. BG Medicine continues to emphasize development of novel diagnostic biomarkers that improve clinical management of heart failure and other cardiovascular conditions, maintaining strategic alliances with major diagnostic and healthcare companies to expand reach and enhance clinical offerings. BG Medicine’s diagnostic portfolio and strategic partnerships position it within the cardiovascular diagnostics industry segment, targeting physicians, clinical laboratories, and healthcare systems, with an emphasis on improving patient risk assessment and management through biomarker innovation. The company leverages its proprietary biomarkers to aid in predicting patient responses to therapy, disease progression monitoring, and prognosis determination. Its business model focuses on research collaboration, licensing, and commercialization agreements with global diagnostic firms to broaden test availability and application. Overall, BG Medicine operates as a specialized cardiovascular diagnostics entity with a focus on proprietary biomarker tests, strategic partnerships for product commercialization, and ongoing efforts to refine its regulatory and clinical pathways to optimize market presence and patient impact. The company remains headquartered in Massachusetts, with no recent indications of geographic expansion beyond the U.S. market as of the latest available information in 2025. This description reflects BG Medicine's current product offerings, business model, and recent company changes through 2025.
Progyny (NASDAQ:PGNY) versus BG Medicine (OTCMKTS:BGMD) Head-To-Head Contrast
Critical Comparison: BG Medicine (OTCMKTS:BGMD) and Alignment Healthcare (NASDAQ:ALHC)
Ardent Health (NYSE:ARDT) vs. BG Medicine (OTCMKTS:BGMD) Head-To-Head Comparison